Adam Zuiani

Adam Zuiani is a Senior Scientist II in Systems Immunology at BioNTech US, serving as the scientific lead for BNT166, the company's mpox vaccine candidate since November 2021. Prior to this role, Adam Zuiani was a Senior Scientist in Systems Immunology at Harvard Medical School, where Adam designed and conducted extensive studies on antibody and B cell biology, co-leading a significant study published in Cell in 2020 that linked rapid resolution of mild-moderate COVID-19 with superior germinal center-derived antibody responses. Adam Zuiani's academic background includes a PhD in Immunology from Washington University in St. Louis and a Bachelor of Science in Microbiology from the University of Guelph. Early in Adam Zuiani's career, experience was gained in various research roles, including developing a mutagenesis approach for studying rapidly mutating viruses and conducting structure-function studies on bacterial transporters.